Dalpiciclib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase II drugs for Oropharyngeal Cancer have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Dalpiciclib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dalpiciclib isethionate (Erlikon) is a hypoglycemic agent. It is formulated as tablets for oral route of administration. Erlikon is indicated for hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative endocrine therapy in combination with fulvestrant and post-progressed recurrent or metastatic breast cancer, HER2+ breast cancer, well-differentiated and dedifferentiated liposarcoma.
It was also under development for hepatocellular carcinoma, non-small cell lung cancer and metastatic colorectal cancer.
Jiangsu Hengrui Medicine overview
Jiangsu Hengrui Medicine (Jiangsu Hengrui) is a biopharmaceutical company that focuses on the research, development, manufacture, and distribution of novel pharmaceutical products. Its product portfolio includes anti-tumor drugs, surgical drugs, contrast agents, angiomyocardiac drugs, and antibiotics. The company is also developing pipeline products for the treatment of cancer, Crohn’s disease, anemia, diabetes, atopic dermatitis, chronic bone disease, blood pressure, and hypercholesterolemia. Jiangsu Hengrui has R&D facilities in China, the US, and Japan. The company offers products through its sales and distribution network in China, the US, Japan, Germany Switzerland, and Australia. Jiangsu Hengrui is headquartered in Lianyungang, Jiangsu Province, China.
For a complete picture of Dalpiciclib’s drug-specific PTSR and LoA scores, buy the report here.